Short answer
ARS Pharmaceuticals, Inc. (SPRY) filed an 8-K current report with the SEC on June 25, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). Stockholders re-elected Saqib Islam, Phillip Schneider, and Laura Shawver as Class III directors through the 2029 annual meeting.
ARS Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Stockholders re-elected Saqib Islam, Phillip Schneider, and Laura Shawver as Class III directors through the 2029 annual meeting
- Director support varied, with Phillip Schneider receiving 38,474,013 votes for versus 27,543,772 withheld
- Ernst & Young ratified as independent auditor for fiscal year ending December 31, 2026, with 79,465,541 votes for
- Executive compensation approved on an advisory basis, with 57,290,450 votes for and 8,104,466 against
- Annual say-on-pay voting adopted through no later than the 2032 annual meeting, aligning with the board’s recommendation
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ARS Pharmaceuticals, Inc. 8-K filings
Get the next SPRY 8-K as it lands
Follow SPRY for push alerts, or ask the research agent what this filing means.